Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ja Min Byun

Showing results (121-130 of 123) with videos related to

Pageof 13
Sort By:
You have reached the last page of results.This site can display upto 123 results.
Clinical Lymphoma, Myeloma & Leukemia|December 12, 2025
Linvoseltamab in Patients With Relapsed/Refractory Multiple Myeloma in the LINKER-MM1 Study: Longer Follow-Up and Subgroup AnalysesHans C Lee, Jeffrey A Zonder, Madhav V Dhodapkar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 16, 2024
Linvoseltamab for Treatment of Relapsed/Refractory Multiple MyelomaNaresh Bumma, Joshua Richter, Sundar Jagannath, et al.
Haematologica|June 6, 2024
Superior outcomes and high-risk features with carfilzomib, lenalidomide, and dexamethasone combination therapy for patients with relapsed and refractory multiple myeloma: results of the multicenter KMMWP2201 studyJi Hyun Lee, Jimin Choi, Chang-Ki Min, et al.
Pageof 13

Showing results (121-130 of 123) with videos related to

Sort By:
Pageof 13
You have reached the last page of results.This site can display upto 123 results.
Clinical Lymphoma, Myeloma & Leukemia|December 12, 2025
Linvoseltamab in Patients With Relapsed/Refractory Multiple Myeloma in the LINKER-MM1 Study: Longer Follow-Up and Subgroup AnalysesHans C Lee, Jeffrey A Zonder, Madhav V Dhodapkar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 16, 2024
Linvoseltamab for Treatment of Relapsed/Refractory Multiple MyelomaNaresh Bumma, Joshua Richter, Sundar Jagannath, et al.
Haematologica|June 6, 2024
Superior outcomes and high-risk features with carfilzomib, lenalidomide, and dexamethasone combination therapy for patients with relapsed and refractory multiple myeloma: results of the multicenter KMMWP2201 studyJi Hyun Lee, Jimin Choi, Chang-Ki Min, et al.
Pageof 13